Therapists are integral to psychedelic-assisted psychotherapy, and the need to provide accessible and robust training experiences for therapists is a crucial objective as the need for psychedelic-assisted treatment continues to grow. ATMA is committed to building out infrastructure for the psychedelic therapy industry by addressing obstacles to accessibility for Canadians seeking psychedelic treatment.
ATMA Co-CEO Vu Tran sees the importance of preparation without delay.
ATMA is pleased to announce the completion of its first clinical trial application (CTA). The phase II open-label single arm study, led by psychiatrist Dr. Ravinder Bains, aims to assess the safety and psychological outcome of psilocybin when administered to healthy participants enrolled in a psychedelic assisted therapy training program offered by ATMA. Physiological outcome will be assessed by documenting vital signs including heart rate, blood pressure, and body temperature after administration of dried mushrooms (psilocybin) over a 6-hour experimental session, while the psychological outcome will be documented by pre-and post-session self-assessment, including the QIDS-SR16 and MEQ30 questionnaires. With growing interest in clinical applications of psilocybin to treat depression, post-traumatic stress disorder, and substance abuse disorders, the physiological data gleaned from this study will provide much-needed ‘healthy control’ information.
Mental health care providers who want to complete experiential learning with psychedelic medicines are currently tasked to travel out of Canada to seek these experiences. There have not been experiential learning opportunities made available to therapists in Canada. If ATMA’s application to Health Canada is successful, therapists will now be able to engage in experiential learning and training opportunities on Canadian soil. It is anticipated that therapists who have an experiential understanding of psychedelic medicines will demonstrate increased efficacy in providing psychedelic-assisted psychotherapies.
In partnership with Wayfound Mental Health Group, ATMA aims to create the framework and groundwork for all mental health professionals seeking to adopt psychedelic-assisted psychotherapy. ATMA Co-CEO Vu Tran sees the importance of competency in this offering.
ABOUT ATMA JOURNEY CENTERS INC.
ATMA is a Canadian company focused on delivering practical and innovative healing and transformative experiences that leverage the potential of psychedelic medicine to awaken the inner healer and allow a deeper connection with self, with others, and with the beauty of our world. ATMA was the first private company in Canada to conduct legal psychedelic-assisted therapy with psilocybin, one of the active hallucinogens found in ‘magic mushrooms. For more information, visit www.atmajourney.com.
ABOUT WAYFOUND MENTAL HEALTH GROUP
Wayfound Mental Health Group Inc., and its predecessor companies, have been proudly serving the community in Calgary since 1999. Wayfound has grown to become a national mental health service provider and, in addition to work in psychedelic training, is focused on innovation in mental health program development and delivery. The mental health professionals at Wayfound bring years of experience working with clients across the lifespan and suffering from various mental health conditions. Wayfound focuses on service provision for first responders and public safety personnel who have suffered operational stress injuries in the line of duty. The organization believes that access to mental health care should be a right, not a privilege, and they advocate for the importance of mental health care being as commonplace as physical health care.
MEDIA CONTACT: David Harder, Co-CEO, ATMA Journey Centers Inc., email@example.com